36 results about "Serum creatinine level" patented technology

A continuous Glomerular Filtration Rate (GFR) estimation system may include a Foley catheter, a continuous urine creatinine sensor, and a urine output monitor. The continuous GFR estimation system computes creatinine clearance as CrCl=(Ucr×Uvol) / Pcr×Tmin), where Ucr is urine creatinine in mg / dL, Uvol is urine volume in mL, Pcr is plasma (serum) creatinine in mg / dL, and Tmin is time in minutes. A Foley catheter may be used to withdraw urine from the bladder. The urine may be delivered to a urine output monitor that provides the Uvol value over a time Tmin. Attached to the catheter is the flow-through continuous urine creatinine sensor for providing the Ucr value. The remaining parameter is Pcr. Because serum creatinine levels do not change rapidly over time, a blood sample may be withdrawn prior to the start of the continuous GFR to obtain the Pcr value.

Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to ameliorate renal failure (e.g., improved diuretic effect and / or lowering blood urea nitrogen, proteinuria, and / or serum creatinine levels) in a subject as a result of having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making and using such compositions.

The present invention addresses the problem of identifying a biomarker of renal failure, said biomarker being available from urine or blood, and fluctuating from an early stage than glomerular filtration rate and serum creatinine level, and thus developing a technique for diagnosing early stage kidney failure. A method for analyzing the blood, plasma, serum or urine of a renal failure suspected subject comprises a step of measuring the concentration of a pair of D-form and L-form of at least one amino acid selected from the amino acid group consisting of [D-serine] and [L-serine], etc., contained in the blood, plasma, serum or urine of the subject, and calculating, as an pathological index of the subject, the ratio of the D-form concentration to the L-form concentration or the percentage of the D-form concentration relative to the total concentration of the D-form and L-form.

The invention provides application of brown algae oligosaccharide or pharmaceutically acceptable salt thereof in preparation of a medicine for treating acute kidney injury, wherein the brown algae oligosaccharide is brown algae disaccharide, brown algae triose and / or brown algae tetraose. The invention also provides application of the brown algae oligosaccharide or the pharmaceutically acceptable salt thereof in preparation of medicines for preventing acute kidney injury from being converted into chronic kidney diseases. After the brown algae oligosaccharide is used for treating an animal with acute kidney injury, the serum creatinine level is obviously reduced, the urine concentration function of the kidney is obviously recovered, the levels of renal tubular injury factors (KIM-1 and NGAL) are obviously reduced, the expression of inflammatory factors is obviously reduced, the pathological change of the kidney is obviously improved, and the treatment effect is enhanced along with the increase of the dosage. Therefore, the brown algae oligosaccharide disclosed by the invention has a relatively strong effect of treating the acute kidney injury. In addition, when acute kidney injury occurs, the brown algae oligosaccharide disclosed by the invention can be used for protecting kidney functions and preventing the acute kidney injury from being converted into chronic kidney diseases.

This invention comprises a chlorophyllin composition and method of administering the same for using the same for treatment of kidney disease patients to achieve decrease in serum creatinine level. The chlorophyllin composition and its method of administration is also for concurrent increase in blood hemoglobin level. The Chlorophyllin is selected from the group consisting of sodium copper chlorophyllin, Potassium copper chlorophyllin, Potassium Iron chlorophyllin and other metal containing chlorophyllin / s. To the chlorophyllin composition are added additives, optionally, (a) a diluent, excipient or a carrier, and optionally (b) the chlorophyllin composition is administered, either concurrently, sequentially or in any other order, with other ingredients / compositions supportive for kidney function. The dosage form of composition comprises a liquid, powder, tablet and a capsule. A kit is also provided comprising the chlorophyllin composition and the additional ingredients. The other ingredients comprise amino acids taken individually or as a mixture, protein hydrolysate, proteins or protein concentrates, vitamins and minerals.

The invention discloses a hippophae rhamnoides extract capable of preventing and treating gout. The hippophae rhamnoides extract is prepared by the following steps: taking a certain amount of hippophae rhamnoides, crushing and sieving, adding a certain amount of solvent for extraction, filtering, merging filtrate and concentrating to obtain the hippophae rhamnoides extract. Animal experiment research shows that the hippophae rhamnoides fruit extract with the gout prevention and treatment effect can remarkably reduce the uric acid and blood urea nitrogen level of an acute hyperuricemia model mouse. In the experiment process, although the allopurine with a large dose of a positive drug has an obvious uric acid reducing effect, the allopurine has an obvious renal injury effect, and compared with a model group, the allopurine can obviously increase serum creatinine and blood uric acid nitrogen levels. And the sea-buckthorn extract, especially the water extract and ethanol extract of sea-buckthorn, can reduce the blood uric acid level and the blood urea nitrogen level, has no obvious influence on the serum creatinine level, has no obvious adverse reaction, and is safer in clinical application.

The invention discloses lactobacillus reuteri CCFM1132 capable of relieving hyperuricemia and ulcerative colitis and application of the lactobacillus reuteri CCFM1132, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1132 can reduce the serum uric acid level of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) of serum and liver, and reduce the occurrence of hyperuricemia and gout; the serum creatinine level can be lowered, the serum total triglyceride (TG) can be lowered, and the activity of serum alkaline phosphatase (ALP) can be inhibited; and the expression of ileum uric acid transporter ABCG2 is promoted. The lactobacillus reuteri CCFM1132 disclosed by the invention can improve the disease activity index of a patient with colitis, can be used for preparing functional microbial agents, foods and medicines for relieving hyperuricemia, gout and inflammatory bowel diseases, and has a wide application prospect.

The invention provides a single-composition traditional Chinese medicine preparation, and a preparation method and application thereof. The traditional Chinese medicine preparation is characterized by being prepared from a main raw material of an artificially cultivated cicada active component. The single-composition traditional Chinese medicine preparation provided by the invention has obvious treatment and prevention effects on generation and development of chronic renal failure. According to animal experiments, the single-composition traditional Chinese medicine preparation provided by the invention can improve kidney functions, lower serum creatinine level and urea nitrogen level, increase hemoglobin, reduce ECM (extracellular matrix) deposition, mitigate renal tubulointerstitial injury and delay renal interstitial fibrosis; besides the single composition is safe, effective and without obvious toxic or side effects.

The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

The invention discloses a traditional Chinese medicine for treating chronic renal insufficiency. The traditional Chinese medicine is prepared from the following raw materials by weight: 15g of herba epimedii, 20g of fructus lycii, 10g of roasted rhizoma atractylodis macrocephalae, 15g of rhizoma smilacis glabrae, 20g of radix cynanchi paniculati, 20g of raw rhubarb, 10g of pericarpium citri reticulatae, 10g of caulis bambusae in taeniam, 15g of semen plantaginis, 15g of herba leonuri and 9g of radix aconiti lateralis preparata. The traditional Chinese medicine solves the problems that the existing western medicine has no special treatment means for chronic renal insufficiency and is limited to the dilemma of symptomatic support treatment, and is suitable for treating chronic renal insufficiency; and through years of clinical application, the traditional Chinese medicine can quantify urine protein of a patient within 24 hours, reduce the serum creatinine level, increase the endogenous creatinine clearance rate, the erythrocyte count and the hemoglobin level, significantly protect the renal function, reduce the anemia degree of the patient, significantly improve the clinical symptomsof the patient and improve the life quality of the patient.

The present invention provides one kind of Chinese medicine for treating chronic kidney function failure is prepared with Chinese medicinal materials, including ginseng, astragalus root, white atractylodes rhizome, Chuanxiong rhizome, leech, etc. The medicine has high curative effect, can improve clinical symptoms, reduce urea nitrogen in blood, lower creatinine level, reduce exhausted urine protein, protect kidney function, promote the synthesis of plasma protein, raise plasma protein density, improve body's nutrient state and produce many other positive effects. It is safe clinically and low in production cost.

The present invention addresses the problem of identifying a biomarker of renal failure, said biomarker being available from urine or blood, and fluctuating from an early stage than glomerular filtration rate and serum creatinine level, and thus developing a technique for diagnosing early stage kidney failure. A method for analyzing the blood, plasma, serum or urine of a renal failure suspected subject comprises a step of measuring the concentration of a pair of D-form and L-form of at least one amino acid selected from the amino acid group consisting of [D-serine] and [L-serine], etc., contained in the blood, plasma, serum or urine of the subject, and calculating, as an pathological index of the subject, the ratio of the D-form concentration to the L-form concentration or the percentage of the D-form concentration relative to the total concentration of the D-form and L-form.

The invention discloses a medicine composite for preventing or treating a diabetic nephropathy and relates to the technical field of traditional Chinese medicine. The medicine composite is prepared by the following traditional Chinese medicinal raw materials in parts by weight: 15-23 parts of herba epimedii, 15-23 parts of morinda officinalis, 12-18 parts of fructus corni, 12-18 parts of selfheal and 12-18 parts of fructus polygoni orientalis. The medicine composite can reduce fasting blood glucose and excretion of urine protein, lower the serum creatinine level, increase the creatinine clearance rate, and prevent or treat the diabetic nephropathy, and is low in toxic and side effect.

The invention belongs to the field of medicine, and particularly relates to a drug composition for treating diabetic nephropathy, a preparation method and uses thereof. The technical problem solved by the present invention is to provide a completely-new drug composition for treating diabetic nephropathy. According to the drug composition of the present invention, caulis sinomenii, astragalus complanatus, milkvetch root, coptis chinensis and safflower are adopted as main bulk drugs to achieve the diabetic nephropathy treating purpose; and rosa laevigata michx and euryale ferox can further be added so as to further improve the treatment effect of the drug composition. According to the present invention, the most typical symptom of the diabetic nephropathy is nodular glomerulosclerosis and mainly the excretion amount of the urinary albumin is adopted as the diagnostic indicator, and after patients take the drug composition, the proteinuria excretion is significantly reduced, the 24 h urine total protein level and the urinary albumin excretion rate are reduced, the urinary albumin / creatinine ratio is reduced, the serum creatinine level is lowered, the life quality of patients is significantly improved, and the progress of the diabetic nephropathy disease is delayed.

The invention belongs to the field of medicine, and particularly relates to a drug composition for treating diabetic nephropathy, a preparation method and uses thereof. The technical problem solved by the present invention is to provide a completely-new drug composition for treating diabetic nephropathy. According to the drug composition of the present invention, caulis sinomenii, astragalus complanatus, milkvetch root and coptis chinensis are adopted as main bulk drugs to achieve the diabetic nephropathy treating purpose; and rosa laevigata michx and euryale ferox can further be added so as to further improve the treatment effect of the drug composition. According to the present invention, the most typical symptom of the diabetic nephropathy is nodular glomerulosclerosis and mainly the excretion amount of the urinary albumin is adopted as the diagnostic indicator, and after patients take the drug composition, the proteinuria excretion is significantly reduced, the 24 h urine total protein level and the urinary albumin excretion rate are reduced, the urinary albumin / creatinine ratio is reduced, the serum creatinine level is lowered, the life quality of patients is significantly improved, and the progress of the diabetic nephropathy disease is delayed.

This invention comprises a chlorophyllin composition and method of administering the same for using the same for treatment of kidney disease patients to achieve decrease in serum creatinine level. The chlorophyllin composition and its method of administration is also for concurrent increase in blood hemoglobin level. The Chlorophyllin is selected from the group consisting of sodium copper chlorophyllin, Potassium copper chlorophyllin, Potassium Iron chlorophyllin and other metal containing chlorophyllin / s. To the chlorophyllin composition are added additives, optionally, (a) a diluent, excipient or a carrier, and optionally (b) the chlorophyllin composition is administered, either concurrently, sequentially or in any other order, with other ingredients / compositions supportive for kidney function. The dosage form of composition comprises a liquid, powder, tablet and a capsule. A kit is also provided comprising the chlorophyllin composition and the additional ingredients. The other ingredients comprise amino acids taken individually or as a mixture, protein hydrolysate, proteins or protein concentrates, vitamins and minerals.